

117TH CONGRESS
1ST SESSION

S. 2148

To impose sanctions and other measures in response to the failure of the Government of the People's Republic of China to allow an investigation into the origins of COVID–19 at suspect laboratories in Wuhan.

IN THE SENATE OF THE UNITED STATES

JUNE 21, 2021

Mr. RUBIO introduced the following bill; which was read twice and referred to the Committee on Foreign Relations

A BILL

To impose sanctions and other measures in response to the failure of the Government of the People's Republic of China to allow an investigation into the origins of COVID–19 at suspect laboratories in Wuhan.

1 *Be it enacted by the Senate and House of Representa-*

2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Coronavirus Origin

5 Validation, Investigation, and Determination Act of 2021”

6 or the “COVID Act of 2021”.

1 **SEC. 2. MEASURES IN RESPONSE TO FAILURE OF THE GOV-**
2 **ERNMENT OF THE PEOPLE'S REPUBLIC OF**
3 **CHINA TO ALLOW AN INVESTIGATION OF SUS-**
4 **PECT LABORATORIES IN WUHAN.**

5 (a) IN GENERAL.—If, by not later than the date that
6 is 90 days after the date of the enactment of this Act,
7 the President is unable to certify that the Government of
8 the People's Republic of China has allowed a transparent
9 international forensic investigation of suspect laboratories
10 in Wuhan to commence, including the Wuhan Institute of
11 Virology of the Chinese Academy of Sciences (in this sec-
12 tion referred to as “CAS”), the President shall—

13 (1) impose the sanctions described in subsection
14 (c) with respect to individuals who hold positions of
15 leadership in the state-run CAS, including its more
16 than 100 affiliated institutes and laboratories, 13
17 local branches, and 2 universities;

18 (2) prohibit Federal funding for any joint re-
19 search or other collaborative projects between United
20 States-based researchers and CAS researchers
21 across all academic fields, including those employed
22 by any of the more than 100 affiliated institutes and
23 laboratories of CAS, its 13 local branches or 2 uni-
24 versities, or the more than 430 science and tech-
25 nology enterprises based in the People's Republic of

1 China across 11 industries that were created by
2 CAS or founded with CAS investment; and

3 (3) prohibit United States-based researchers
4 and institutions that receive Federal funding from
5 engaging in collaborative projects involving gain-of-
6 function research on viruses with individuals or in-
7 stitutions based in the People's Republic of China.

8 (b) TERMINATION.—The requirements of subsection
9 (a) shall terminate on the date on which the Government
10 of the People's Republic of China allows the transparent
11 international forensic investigation described in that sub-
12 section to be conducted and concluded without—

13 (1) imposition of restrictions on the scope or
14 subject matter of the investigation; or

15 (2) limitations on the access of investigators to
16 physical sites, persons of interest, or relevant epi-
17 miological, serological, and virological data.

18 (c) SANCTIONS DESCRIBED.—The sanctions to be
19 imposed under subsection (a)(1) are the following:

20 (1) ASSET BLOCKING.—

21 (A) IN GENERAL.—The President shall ex-
22 ercise all of the powers granted to the President
23 under the International Emergency Economic
24 Powers Act (50 U.S.C. 1701 et seq.) to the ex-
25 tent necessary to block and prohibit all trans-

1 actions in property and interests in property de-
2 scribed in subparagraph (B) if such property
3 and interests in property are in the United
4 States, come within the United States, or are or
5 come within the possession or control of a
6 United States person.

7 (B) PROPERTY AND INTERESTS IN PROP-
8 ERTY DESCRIBED.—The property and interests
9 in property described in this subparagraph are
10 property or interests in property of—

11 (i) an individual described in sub-
12 section (a)(1); or

13 (ii) any family member or associate
14 acting for or on behalf of an individual de-
15 scribed in subsection (a)(1) and to whom
16 that individual transfers such property or
17 interests in property after the date on
18 which the President designates the indi-
19 vidual for the imposition of sanctions
20 under that subsection.

21 (2) INELIGIBILITY FOR VISAS, ADMISSION, OR
22 PAROLE.—

23 (A) VISAS, ADMISSION, OR PAROLE.—An
24 alien described in subsection (a)(1) is—

25 (i) inadmissible to the United States;

(ii) ineligible to receive a visa or other documentation to enter the United States; and

(iii) otherwise ineligible to be admitted or paroled into the United States or to receive any other benefit under the Immigration and Nationality Act (8 U.S.C. 1101 et seq.).

(B) CURRENT VISAS REVOKED.—

(i) IN GENERAL.—An alien described in subsection (a)(1) is subject to revocation of any visa or other entry documentation regardless of when the visa or other entry documentation is or was issued.

(ii) IMMEDIATE EFFECT.—A revocation under clause (i) shall—

(I) take effect immediately; and

(II) automatically cancel any other valid visa or entry documentation that is in the alien's possession.

(d) IMPLEMENTATION; PENALTIES.—

(1) IMPLEMENTATION.—The President may exercise the authorities provided to the President under sections 203 and 205 of the International Emergency Economic Powers Act (50 U.S.C. 1702

1 and 1704) to the extent necessary to carry out this
2 section.

3 (2) PENALTIES.—A person that violates, at-
4 tempts to violate, conspires to violate, or causes a
5 violation of subsection (c)(1) or any regulation, li-
6 cense, or order issued to carry out that subsection
7 shall be subject to the penalties set forth in sub-
8 sections (b) and (c) of section 206 of the Inter-
9 national Emergency Economic Powers Act (50
10 U.S.C. 1705) to the same extent as a person that
11 commits an unlawful act described in subsection (a)
12 of that section.

13 (e) EXCEPTIONS.—

14 (1) EXCEPTION FOR INTELLIGENCE ACTIVI-
15 TIES.—Sanctions under this section shall not apply
16 to any activity subject to the reporting requirements
17 under title V of the National Security Act of 1947
18 (50 U.S.C. 3091 et seq.) or any authorized intel-
19 ligence activities of the United States.

20 (2) EXCEPTION TO COMPLY WITH INTER-
21 NATIONAL OBLIGATIONS AND FOR LAW ENFORCE-
22 MENT ACTIVITIES.—Sanctions under subsection
23 (c)(2) shall not apply with respect to an alien if ad-
24 mitting or paroling the alien into the United States
25 is necessary—

(B) to carry out or assist law enforcement activity in the United States.

10 (3) EXCEPTION RELATING TO IMPORTATION OF
11 GOODS.—

22 (f) DEFINITIONS.—In this section:

(1) ADMISSION; ADMITTED; ALIEN.—The terms “admission”, “admitted”, and “alien” have the

1 meanings given those terms in section 101 of the
2 Immigration and Nationality Act (8 U.S.C. 1101).

3 (2) GAIN-OF-FUNCTION.—The term “gain-of-
4 function”, with respect to the study of viruses,
5 means—

6 (A) the use of gene editing to increase the
7 transmissibility, virulence, immunogenicity, or
8 host tropism of a virus by artificially inserting
9 genomic components from one virus into the
10 backbone of another virus, which results in the
11 creation of a new chimeric virus, particularly
12 when the resultant chimeric virus is pathogenic
13 to humans; or

14 (B) serial passaging in a cell culture to in-
15 crease the transmissibility, virulence, immuno-
16 genicity, or host tropism of a virus by selec-
17 tively applying pressure to a culture to artifi-
18 cially induce its mutation or RNA recombi-
19 nation with one or more viruses.

20 (3) TRANSPARENT INTERNATIONAL FORENSIC
21 INVESTIGATION.—The term “transparent inter-
22 national forensic investigation”, with respect to in-
23 vestigating the origin of SARS-CoV-2, means an in-
24 quiry that is objective, data-driven, inclusive of
25 broad expertise, subject to independent oversight,

1 and properly managed to exclude individuals with
2 conflicts of interest and under which the following
3 takes place:

4 (A) Relevant research laboratories and
5 hospitals open their records to examination by
6 the investigative team and grant the investiga-
7 tive team unfettered access to any and all facili-
8 ties and other sites of interest, and to any and
9 all forms of epidemiological or virological data
10 of interest, including serological records per-
11 taining to the earliest confirmed or suspected
12 cases of COVID–19, or cases of similar illnesses
13 that may have been misdiagnosed, which ap-
14 peared in and around Wuhan in the fall and
15 winter of 2019. Investigators document the ve-
16 racity and source of the data upon which their
17 analysis is based in a manner that allows inde-
18 pendent experts to reproduce their analysis and
19 validate any conclusions they may draw.

20 (B) The international team is allowed to
21 perform a full forensic investigation of the
22 Wuhan Institute of Virology, and if necessary,
23 the Wuhan Center for Disease Prevention and
24 Control and the Wuhan Institute of Biological
25 Products, and all other laboratories in Wuhan

1 that the team might identify as warranting ex-
2 amination. The team is allowed to review the
3 biosafety level under which bat coronavirus re-
4 search was conducted, and to interview any and
5 all personnel currently or previously employed
6 at those laboratories, or related experts who
7 may have information pertinent to the inves-
8 tigation. All laboratory logs and notebooks kept
9 by Shi Zhengli and other researchers at the
10 Wuhan Institute of Virology who have con-
11 ducted gain-of-function experiments between
12 2007 and the date of the enactment of this Act,
13 as well as their published and unpublished work
14 in Chinese and English, are presented in a full
15 and unaltered condition for examination by the
16 team. The team is given unlimited access to the
17 full range of virus cultures, isolates, genetic se-
18 quences, databases, and patient specimens
19 stored at these facilities as well as all chimeric
20 synthetic viruses grown in vitro by cell culture
21 passaging or engineered by genomic editing be-
22 tween 2007 and the date of the enactment of
23 this Act. Such access must include the oppor-
24 tunity to examine the Wuhan Institute of
25 Virology's database of approximately 22,000

1 samples and virus sequences, including 15,000
2 taken from bats, which was previously available
3 to the public but taken offline in September
4 2019. The team is further allowed to examine
5 in full all training procedures in effect at the
6 laboratory prior to the pandemic, including
7 those pertaining to recordkeeping and safety
8 procedures and strategies to prevent the acci-
9 dental escape of potential pathogens.

10 (C) The investigative team analyzes in de-
11 tail all research related to the 293 bat
12 coronaviruses reportedly isolated by Shi Zhengli
13 and her team at the Wuhan Institute of Virol-
14 ogy between 2012 and 2015, particularly
15 RaTG13 and RaBtCoV/4991, including all
16 virus isolates and cultures. The Wuhan Insti-
17 tute of Virology discloses the content of all clas-
18 sified and unpublished studies that the Institute
19 reportedly conducted with the People's Libera-
20 tion Army if such studies involved gain-of-func-
21 tion research. The team is able to test all lab-
22 oratory personnel for antibodies and other sero-
23 logical indicators of past infection of COVID–
24 19. The team is given access to all other
25 records kept by the Wuhan Institute of Virol-

1 ogy, including security logs, surveillance video
2 footage, audio recordings, and electronic logs of
3 employees entering and leaving the facility. The
4 investigative team is permitted to take samples
5 and conduct testing of the physical facilities
6 where gain-of-function research has been con-
7 ducted, including, if necessary, sewer samples.
8 Unfettered access is also granted to the aban-
9 doned copper mine in Mojiang Hani Autono-
10 mous County in Yunnan province, where
11 Wuhan Institute of Virology researchers are
12 known to have collected bat virus specimens, in-
13 cluding of RaTG13, during the decade pre-
14 ceding the date of the enactment of this Act.

15 (D) The international team is comprised of
16 members chosen by the governments of the
17 United States, Canada, the United Kingdom,
18 France, the Netherlands, Germany, Australia,
19 Japan, and India. The team includes molecular
20 biologists, virologists, epidemiologists, and ex-
21 perts in biosafety and biosecurity. Individuals
22 who have previously ruled out the possibility of
23 either zoonotic transmission or a laboratory
24 leak are disqualified from participation. The
25 Government of the People's Republic of China

1 may appoint Chinese experts to accompany and
2 advise the team as it conducts its work in the
3 People's Republic of China, but the Government
4 of the People's Republic of China has no au-
5 thority to dictate the selection of team members
6 and cannot obstruct the participation of any in-
7 dividual selected by the individual's government
8 for the team. The central, provincial, and mu-
9 nicipal authorities of the People's Republic of
10 China facilitate the work of the investigative
11 team and refrain from imposing any restrictions
12 on the scope, scale, and duration of the inves-
13 tigation.

14 (4) UNITED STATES PERSON.—The term
15 “United States person” means—

16 (A) an individual who is a United States
17 citizen or an alien lawfully admitted for perma-
18 nent residence to the United States;

19 (B) an entity organized under the laws of
20 the United States or any jurisdiction within the
21 United States, including a foreign branch of
22 such an entity; or

23 (C) any person in the United States.

